FDG PET-negative liver metastases of a malignant melanoma and FDG PET-positive hurthle cell tumor of the thyroid.
A Hurthle cell tumor (oncocytoma) of the thyroid presented as a hypermetabolic focus in a fluorodeoxyglucose positron emission tomography (FDG PET) study which was performed as staging procedure in a patient with malignant melanoma. This finding led to the initial diagnosis of a metastasis. In contrast, multiple liver metastases, seen on MRI and sonography, did not show any increased FDG uptake. Cytology results of one liver mass confirmed a melanoma metastasis, and of the neck mass, a Hurthle cell tumor. The Hurthle cell tumor was, based on clinical evidence, thought to be benign. This is the first description of a FDG PET-positive benign Hurthle cell tumor, with FDG PET-negative liver metastases of a malignant melanoma, in the same patient.
Wiesner
W
W
Institute of Diagnostic Radiology, Department of Radiology, Hospital of the University of Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland.
Engel
H
H
von Schulthess
G K
GK
Krestin
G P
GP
Bicik
I
I
D018249:Adenoma, Oxyphilic / Q000000981:diagnostic imaging*; D000368:Aged; D005188:False Negative Reactions; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000556:secondary*; D009378:Neoplasms, Multiple Primary / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D012878:Skin Neoplasms / Q000473:pathology*; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18